Last reviewed · How we verify
NCT04184908: XEROSTOMIA
Clinical Study New Gel for Xerostomia
Phase 1 trial testing gel xerostomia in XEROSTOMIA in 60 participants. Status unknown.
2 November 2019
Quick facts
| Lead sponsor | Universidad de Murcia |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 October 2019 |
| Primary completion | 2 November 2019 |
| Estimated completion | 31 December 2020 |
| Sites | 2 locations across Spain |
Drugs / interventions tested
- gel xerostomia — full drug profile →
- gel placebo
Conditions studied
- XEROSTOMIA — all drugs for XEROSTOMIA →
Sponsor
Universidad de Murcia — full company profile →
Who can join
Adults 18 to 90, any sex, with XEROSTOMIA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present, there is no single consensus protocol for the treatment of oral dryness, although the main objective is to improve the quality of life of patients. Current therapy for the control of xerostomia is based on the following measures: 1. General measures ; review and control of drugs,hydration and dietary advice: The main recommendations are found in the following scheme. 2. Saliva stimulants( Topics and sistemic )The option of using chewing stimuli by chewing gum with non-cariogenic sweeteners helps to improve symptoms. The investigators can also use gustatory stimuli, such as citric acid that is a potent stimulator of salivary secretion. Among the most commonly used pharmacological agents are: pilocarpine, bethanecol, civemiline 3. Saliva substitutes or artificial saliva. Saliva substitutes can provide a moisture retention layer in the oral mucosa and can be administered by liquids, spray, pills or gels. Topical treatments have few adverse effects and improve the quality of life of patients with xerostomia; In addition, they maintain oral health.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Clinical Study on the Efficacy and Tolerability of a New Topical Gel and Toothpaste in Patients with Xerostomia: A Randomized Controlled Trial.
López Jornet P, Hernandez L, Gomez García F, Galera Molero F, et al · · 2021 · cited 4× · PMID 34884343 · DOI 10.3390/jcm10235641
Verify or expand the search:
- PubMed search for NCT04184908
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Universidad de Murcia trials
Trials by the same sponsor.
- NCT07310459 — Perinatal Risk Factors in Motor Development · not yet recruiting
- NCT06982456 — Manual Therapy Techniques for Cervical Pain: Algometric Evaluation · NA · enrolling by invitation
- NCT06910150 — Effectiveness of a Session of Analgesic Electrostimulation (Invasive and Non-invasive) Applied to the Quadriceps Muscle · NA · enrolling by invitation
- NCT06206499 — Laterally Rotated Flap for Soft Tissue Augmentation Around Maxillary Loaded Osseointegrated Dental Implant · NA · unknown
- NCT06240416 — Autogenous Particles Harvesting During Implant Surgery · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04184908 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad de Murcia
- Last refreshed: 5 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04184908.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing